CIK 0001601830 · Large accelerated filer
RECURSION PHARMACEUTICALS, INC.
Sign in to watch- Ticker
- RXRX
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 464099738
- Phone
- (385) 269-0203
- Business address
- 41S RIO GRANDE STREET, SALT LAKE CITY, UT, 84101
- Former names
- Recursion Pharmaceuticals, LLC
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $701,222
- in 5 filings, $701K under 10b5-1 plans
Net −$701,222. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2026-05-07 | Gibson Christopher Director | Conversion 10b5-1 | +60,000 | 966,556 | ||
| 2026-05-07 | Gibson Christopher Director | Sale 10b5-1 | −40,000 | $3.37 | $135K | 926,556 |
| 2026-05-07 | Gibson Christopher Director | Gift 10b5-1 | −20,000 | 906,556 | ||
| 2026-05-07 | Gibson Christopher Director | Conversion · Class B Common Stock 10b5-1 | −60,000 | 4,343,334 | ||
| 2026-05-05 | Borgeson Blake Director | Sale 10b5-1 | −30,000 | $3.52 | $106K | 6,199,863 |
| 2026-04-22 | Gibson Christopher Director | Conversion 10b5-1 | +40,000 | 946,556 | ||
| 2026-04-22 | Gibson Christopher Director | Sale 10b5-1 | −40,000 | $3.61 | $144K | 906,556 |
| 2026-04-22 | Gibson Christopher Director | Conversion · Class B Common Stock 10b5-1 | −40,000 | 4,403,334 | ||
| 2026-04-07 | Gibson Christopher Director | Conversion 10b5-1 | +40,000 | 946,556 | ||
| 2026-04-07 | Gibson Christopher Director | Sale 10b5-1 | −40,000 | $3.10 | $124K | 906,556 |
| 2026-04-07 | Gibson Christopher Director | Conversion · Class B Common Stock 10b5-1 | −40,000 | 4,443,334 | ||
| 2026-04-07 | Borgeson Blake Director | Sale 10b5-1 | −30,000 | $3.10 | $93K | 6,229,863 |
| 2026-04-06 | Taylor Ben R Chief Financial Officer | Shares withheld for taxes | −48,028 | $3.11 | $149K | 1,132,290 |
| 2026-04-01 | Dar Zavain Director | Grant or award | +4,902 | 147,231 | ||
| 2026-04-01 | Li Dean Y Director | Grant or award | +3,268 | 1,244,177 | ||
| 2026-03-23 | Gibson Christopher Director | Conversion 10b5-1 | +40,000 | 946,556 | ||
| 2026-03-23 | Gibson Christopher Director | Sale 10b5-1 | −40,000 | $3.25 | $130K | 906,556 |
| 2026-03-23 | Gibson Christopher Director | Conversion · Class B Common Stock 10b5-1 | −40,000 | 4,483,334 | ||
| 2026-03-17 | Taylor Ben R Chief Financial Officer | Sale 10b5-1 | −7,956 | $3.39 | $27K | 1,180,318 |
| 2026-03-16 | Taylor Ben R Chief Financial Officer | Shares withheld for taxes 10b5-1 | −7,075 | $3.42 | $24K | 1,188,274 |
Page 3 of 9 · 179 trades